IP Verse

Micronised Particles Of Low-Dosage Strength Active Agents For Powder Formulations For Inhalation - EP2104490

The patent EP2104490 was granted to Chiesi Farmaceutici on Jun 26, 2024. The application was originally filed on Dec 13, 2007 under application number EP07859026A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2104490

CHIESI FARMACEUTICI
Application Number
EP07859026A
Filing Date
Dec 13, 2007
Status
Patent Maintained As Amended
May 24, 2024
Grant Date
Jun 26, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDApr 3, 2020MAIWALDADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2003165436
INTERNATIONAL-SEARCH-REPORTUS2003180227
INTERNATIONAL-SEARCH-REPORTUS2005175549
INTERNATIONAL-SEARCH-REPORTUS6284287
INTERNATIONAL-SEARCH-REPORTWO0105429
INTERNATIONAL-SEARCH-REPORTWO0200199
INTERNATIONAL-SEARCH-REPORTWO2005013963
INTERNATIONAL-SEARCH-REPORTWO2005089717
INTERNATIONAL-SEARCH-REPORTWO9524889
OPPOSITIONUS2003180227
OPPOSITIONWO2005089717
OPPOSITIONWO2008084312

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- P LE SOUEF, "The meaning of lung dose", ALLERGY, (1999), vol. 54, pages 93 - 96-
INTERNATIONAL-SEARCH-REPORT- GUCHARDI ET AL, "Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (20080204), vol. 348, no. 1-2, ISSN 0378-5173, pages 10 - 17, XP022393884 [PX] 1,3-10,14-21,26 * abstract * * page 11, column L, paragraph L - column R, paragraph 2 * * page 16, column R, paragraphs 1-5 *
OPPOSITION- ARMANNI et al., "In vitro and in vivo drug delivery from the NEXT? DPI (Part 3)", Resp. Drug Delivery, (20060000), pages 561 - 564, XP055721130-
OPPOSITION- BRAMBILLA et al., "Designing a novel dry powder inhaler: The NEXT TM DPI (Part 1)", Resp. Drug Delivery, (20060000), pages 553 - 556, XP055721327-
OPPOSITION- BRAMBILLA G. et al., "Formulation Development for the NEXT? DPI (Part 2)", Resp. Drug Delivery, (20060000), pages 557 - 560, XP055721329-
OPPOSITION- DUTTA et al., "beta-Agonists", Med. Clin. N. Am., (20020900), vol. 86, no. 5, pages 991 - 1008, XP055721323-
OPPOSITION- "Foradil® Label", FDA, (20010900), pages 1 - 27, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20831s2lbl.pdf, XP055721325-
OPPOSITION- CAZZOLA et al., "Ultra long-acting p2-agonists in development for asthma and chronic obstructive pulmomary disease", Expert Opin. Investig. Drugs, (20050701), vol. 14, no. 7, pages 775 - 783, XP003026042

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents